Evidence map›Paper›PMID 42597006›Full record

ArticlePregnancy (Hoboken, N.J.)2026

Perinatal outcomes associated with magnesium sulfate for preeclampsia without severe features.

Samantha E Howell, Christina T Blanchard, Morgan Jenkins, Grace Lee, Macie L Champion, Michelle Lu, Ashley N Battarbee, Brian M Casey, Akila Subramaniam

Abstract read
In one paragraph

Article in Pregnancy (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Samantha E HowellDepartment of Obstetrics and Gynecology Center for Women's Reproductive Health at the University of Alabama at Birmingham Birmingham Alabama USA.ORCID https://orcid.org/0009-0007-5918-9142
Christina T BlanchardDepartment of Obstetrics and Gynecology Center for Women's Reproductive Health at the University of Alabama at Birmingham Birmingham Alabama USA.
Morgan JenkinsDepartment of Obstetrics and Gynecology Center for Women's Reproductive Health at the University of Alabama at Birmingham Birmingham Alabama USA.
Grace LeeDepartment of Obstetrics and Gynecology Center for Women's Reproductive Health at the University of Alabama at Birmingham Birmingham Alabama USA.
Macie L ChampionDepartment of Obstetrics and Gynecology Division of Maternal Fetal Medicine Center for Women's Reproductive Health at the University of Alabama at Birmingham Birmingham Alabama USA.
Michelle LuDepartment of Obstetrics and Gynecology Center for Women's Reproductive Health at the University of Alabama at Birmingham Birmingham Alabama USA.
Ashley N BattarbeeDepartment of Obstetrics and Gynecology Division of Maternal Fetal Medicine Center for Women's Reproductive Health at the University of Alabama at Birmingham Birmingham Alabama USA.
Brian M CaseyDepartment of Obstetrics and Gynecology Division of Maternal Fetal Medicine Center for Women's Reproductive Health at the University of Alabama at Birmingham Birmingham Alabama USA.
Akila SubramaniamDepartment of Obstetrics and Gynecology Division of Maternal Fetal Medicine Center for Women's Reproductive Health at the University of Alabama at Birmingham Birmingham Alabama USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To evaluate neonatal outcomes in patients with preeclampsia without severe features who received magnesium for seizure prophylaxis. Methods: Retrospective cohort study of patients with preeclampsia without severe features delivering ≥32 weeks' gestation at our institution (November 2021-May 2023). The primary outcome was a composite of adverse neonatal outcomes (neonatal intensive care unit [NICU] admission, umbilical artery pH < 7.1, umbilical artery base deficit ≥12, 5-min Apgar <3, neonatal death, culture proven sepsis, and mechanical ventilation). Secondary outcomes included the individual components of the neonatal composite and a maternal bleeding composite. Patients were categorized into those who received intrapartum magnesium and those who did not. Baseline characteristics and outcomes were compared between groups. Multivariable logistic regression estimated the association between magnesium and outcomes, adjusting for characteristics that differed between groups. Results: Of 5327 individuals included in our analysis, 583 met study criteria-439 (75%) received magnesium and 144 (25%) did not. Patients who received magnesium were more likely to have public insurance, medical comorbidities, antenatal aspirin use, earlier gestational age (GA) at delivery, and chorioamnionitis. The odds of composite adverse neonatal outcome were higher in patients who received magnesium (53% vs. 29%; adjusted odds ratio [aOR], 1.85; 95% confidence interval [CI], 1.13-3.04) than those who did not. This was primarily driven by increased odds of NICU admission (aOR, 2.46; 95% CI, 1.46-4.14). When excluding NICU admission from the neonatal composite, there was a significant reduction in the neonatal adverse composite among the magnesium cohort (aOR, 0.43; 95% CI, 0.21-0.88). In addition, the odds of neonatal acidemia were also lower in those who received magnesium (aOR, 0.36; 95% CI, 0.15-0.88). Conclusion: While we found an increase in overall adverse neonatal outcomes in patients receiving magnesium for seizure prophylaxis for preeclampsia without severe features, we also noted discordant findings of decreased neonatal acidemia and neonatal morbidity when excluding NICU admission. As there is no consensus for intrapartum magnesium administration for patients with preeclampsia without severe features, these results suggest further study of risks and benefits of intrapartum magnesium sulfate is warranted.

Indexed as

magnesium sulfateneonatal acidemianeonatal outcomesNICU admissionpreeclampsiaseizure prophylaxis

Identifiers

PMID42597006
PMCPMC13344299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.